Aktis Oncology, Inc.
NASDAQ:AKTSBiotechnology
+$0.11 today
- Market cap
- $865.32M
- Beta
- 1.10
- P/E (TTM)
- -28.7
- EPS (TTM)
- -$0.82
Volume 0.44M
Average 0.33M
AKTS Total Assets
Everything the company owns or controls; equal to total liabilities plus equity.
Aktis Oncology, Inc.NASDAQ: AKTS
Total Assets · Q1 FY2026 · quarter ended Mar 2026
Total assets of $576.8M in Q1 FY2026
Q1 FY2026 total assets was $576.8M. Over 3 fiscal years it compounded at +24.2% a year.
Context
- Total assets increased in 1 of the last 3 fiscal years.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Assets history
USD · from the balance sheet
- Latest · FY2025
- 264.89M USD
- Year-over-year change
- -18.8%
- 3-year CAGR
- +24.2%
| Period | Period end | Total Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 264.89M | -18.8% |
| FY2024 | 2024-12-31 | 326.18M | +166.6% |
| FY2023 | 2023-12-31 | 122.36M | -11.5% |
| FY2022 | 2022-12-31 | 138.32M | — |
Total Assets vs competitors
How AKTS compares with its peers on the latest reported figures
- AKTS's Mar 2026 total assets of $576.8M is the 3rd highest of the 6 companies compared; the peer median is $505.53M.
- Over three fiscal years its annual growth of +24.2% compares with a peer median of +20.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR |
|---|---|---|---|---|
| Mar 2026 | $1.07B | +4.3% | +26.5% | |
| Mar 2026 | $652.4M | -26.2% | +20.5% | |
| Mar 2026 | $576.8M | — | +24.2% | |
| Sep 2026 | $505.53M | +68.9% | +205.1% | |
| Mar 2026 | $217.87M | -3.0% | -3.9% | |
| Mar 2026 | $137.68M | -11.4% | -8.9% | |
| Peer median (excluding AKTS) | $505.53M | -3.0% | +20.5% | |
Competitors are the stored peer set for AKTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Aktis Oncology, Inc.
NASDAQ:AKTS
Intrinsic Alpha fair value
Locked
Current Price
$16.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.